Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with ¹⁷⁷Lu-PSMA and Combined ²²⁵Ac- and ¹⁷⁷Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation.

ABSTRACT:

Purpose

PSMA-targeted radioligand therapy (PRLT) is a promising treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). However, a high uptake of the radiopharmaceutical in the salivary glands (SG) can lead to xerostomia and becomes dose-limiting for ²²⁵Ac-PSMA-617. This study investigated the sialotoxicity of ¹⁷⁷Lu-PSMA-I&T/-617 monotherapy and co-administered ²²⁵Ac-PSMA-617 and ¹⁷⁷Lu-PSMA-617 (Tandem-PPRLT).

Methods

Three patient cohorts, that had undergone ¹⁷⁷Lu-PSMA-I&T/-617 monotherapy or Tandem-PRLT, were retrospectively analyzed. In a short-term cohort (91 patients), a xerostomia assessment (CTCAE v.5.0), a standardized questionnaire (sXI), salivary gland scintigraphy (SGS), and

SUBMITTER: Langbein T 

PROVIDER: S-EPMC9406477 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature